RMS2
MCID: RHB024
MIFTS: 65

Rhabdomyosarcoma 2 (RMS2)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Rhabdomyosarcoma 2

MalaCards integrated aliases for Rhabdomyosarcoma 2:

Name: Rhabdomyosarcoma 2 56 73
Alveolar Rhabdomyosarcoma 12 52 58 29 6 15 17 71
Rhabdomyosarcoma Alveolar 52 73 54 39
Rhabdomyosarcoma, Alveolar 56 74 43
Alveolar Childhood Rhabdomyosarcoma 12 71
Rhabdomyosarcoma 2, Alveolar 56 13
Rms2 56 73
Rmsa 56 73
Rhabdomyosarcoma, Alveolar; Rmsa 56
Arms 52

Characteristics:

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
rhabdomyosarcoma 2:
Inheritance autosomal recessive inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:4051
OMIM 56 268220
MeSH 43 D018232
NCIt 49 C3749 C7958
SNOMED-CT 67 63449009
MESH via Orphanet 44 D018232
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0206655
Orphanet 58 ORPHA99756
MedGen 41 C0206655
SNOMED-CT via HPO 68 124975008 258211005 404053004
UMLS 71 C0206655 C0279613

Summaries for Rhabdomyosarcoma 2

UniProtKB/Swiss-Prot : 73 Rhabdomyosarcoma 2: A form of rhabdomyosarcoma, a highly malignant tumor of striated muscle derived from primitive mesenchymal cells and exhibiting differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is one of the most frequently occurring soft tissue sarcomas and the most common in children. It occurs in four forms: alveolar, pleomorphic, embryonal and botryoidal rhabdomyosarcomas.

MalaCards based summary : Rhabdomyosarcoma 2, also known as alveolar rhabdomyosarcoma, is related to rare tumor and soft tissue sarcoma. An important gene associated with Rhabdomyosarcoma 2 is PAX3 (Paired Box 3), and among its related pathways/superpathways are Pathways in cancer and Glioma. The drugs Olmesartan and Enoxaparin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and prostate, and related phenotypes are alveolar rhabdomyosarcoma and cellular

Wikipedia : 74 Alveolar rhabdomyosarcoma (ARMS) is a sub-type of the rhabdomyosarcoma soft tissue cancer family whose... more...

More information from OMIM: 268220

Related Diseases for Rhabdomyosarcoma 2

Diseases in the Rhabdomyosarcoma family:

Rhabdomyosarcoma 2

Diseases related to Rhabdomyosarcoma 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 rare tumor 31.1 EWSR1 DES
2 soft tissue sarcoma 31.1 MDM2 FOXO1 EWSR1
3 orbit rhabdomyosarcoma 31.0 PAX3 MYOG MB
4 spindle cell sarcoma 31.0 MYOG MDM2 DES
5 desmoplastic small round cell tumor 30.9 WT1 EWSR1 DES
6 familial retinoblastoma 30.9 MYCN MDM2 CDK4
7 skeletal muscle neoplasm 30.9 RHD MYOG MYOD1 MB
8 breast rhabdomyosarcoma 30.9 PAX3 MYOG MYOD1 MB FOXO1 ENO2
9 waardenburg's syndrome 30.8 PAX7 PAX3 MYOD1
10 beckwith-wiedemann syndrome 30.7 WT1 TH MYOD1 IGF1R
11 small cell carcinoma 30.7 WT1 MYCN ENO2 ALK
12 pleomorphic rhabdomyosarcoma 30.7 PAX7 PAX3 MYOG MYOD1 MB FOXO1
13 chondrosarcoma 30.7 MDM2 EWSR1 ENO2 CDK4
14 connective tissue benign neoplasm 30.6 MDM2 ENO2 CDK4
15 retinoblastoma 30.6 MYOD1 MYCN MDM2 ENO2 CDK4
16 alveolar soft part sarcoma 30.6 MYOG MYOD1 MB ENO2 DES
17 cellular myxoid liposarcoma 30.6 MDM2 EWSR1 CDK4
18 olfactory neuroblastoma 30.6 MB EWSR1 ENO2
19 mesenchymal chondrosarcoma 30.5 MYOG MYOD1 ENO2 DES
20 botryoid rhabdomyosarcoma 30.5 PAX3 MYOG MYOD1 MB DES
21 malignant mesenchymoma 30.4 MYOG MYOD1 MDM2 MB DES
22 fibrous histiocytoma 30.4 EWSR1 ENO2 DES ALK
23 neuroblastoma 30.2 TH MYCN MDM2 IGF1R EWSR1 ENO2
24 malignant fibroxanthoma 30.2 MYOG MYOD1 MDM2 DES CDK4 ALK
25 liposarcoma 30.2 MYOG MDM2 MB IGF1R EWSR1 DES
26 wilms tumor 1 30.2 WT1 MYOG MYCN IGF1R EWSR1 ENO2
27 leiomyosarcoma 30.1 WT1 MYOG MDM2 MB ENO2 DES
28 sarcoma 30.1 WT1 MYOG MYOD1 MDM2 IGF1R FOXO1
29 histiocytoma 29.9 MYOG MYOD1 MDM2 MB EWSR1 ENO2
30 leukemia, acute myeloid 29.9 WT1 MYCN MDM2 FOXO1 EWSR1 DIABLO
31 sarcoma, synovial 29.8 WT1 PAX3 MYOG MYCN MDM2 IGF1R
32 ewing sarcoma 29.7 WT1 PAX7 PAX3 MYOG MYCN MDM2
33 embryonal rhabdomyosarcoma 29.6 PAX7 PAX3 MYOG MYOD1 MYCN MDM2
34 muscle cancer 29.4 RMST RHD PAX7 PAX3 MYOG MYOD1
35 skeletal muscle cancer 29.3 WT1 RMST RHD PAX7 PAX3 MYOG
36 rhabdomyosarcoma 28.8 RMST PAX7 PAX3 MYOG MYOD1 MYCN
37 mixed type rhabdomyosarcoma 11.4
38 orbit alveolar rhabdomyosarcoma 11.4
39 central nervous system rhabdomyosarcoma 10.7 PAX3 FOXO1
40 conventional leiomyosarcoma 10.7 PAX7 MYOG
41 myoblastoma 10.7 MYOG ENO2
42 malignant sertoli-leydig cell tumor 10.7 MYOG MYOD1
43 clear cell basal cell carcinoma 10.7 PAX7 PAX3 MYOG
44 ovarian mesodermal adenosarcoma 10.7 WT1 MYOG
45 ring chromosome 7 10.7 MDM2 CDK4
46 mediastinum liposarcoma 10.7 MDM2 CDK4
47 gastric liposarcoma 10.7 MDM2 CDK4
48 spermatic cord cancer 10.7 WT1 MYOD1
49 diffuse lipomatosis 10.7 MDM2 CDK4
50 spindle cell liposarcoma 10.6 MDM2 CDK4

Graphical network of the top 20 diseases related to Rhabdomyosarcoma 2:



Diseases related to Rhabdomyosarcoma 2

Symptoms & Phenotypes for Rhabdomyosarcoma 2

Human phenotypes related to Rhabdomyosarcoma 2:

31
# Description HPO Frequency HPO Source Accession
1 alveolar rhabdomyosarcoma 31 HP:0006779

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
alveolar rhabdomyosarcoma

Clinical features from OMIM:

268220

MGI Mouse Phenotypes related to Rhabdomyosarcoma 2:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDK4 DES DIABLO ENO2 FOXO1 IGF1R
2 behavior/neurological MP:0005386 10.38 ALK CDK4 DES DIABLO ENO2 FOXO1
3 growth/size/body region MP:0005378 10.37 ALK CDK4 DIABLO ENO2 FOXO1 IGF1R
4 homeostasis/metabolism MP:0005376 10.35 ALK CDK4 DES FOXO1 IGF1R MB
5 cardiovascular system MP:0005385 10.3 CDK4 DES FOXO1 IGF1R MB MDM2
6 mortality/aging MP:0010768 10.25 ALK CDK4 DES FOXO1 IGF1R MB
7 embryo MP:0005380 10.22 CDK4 FOXO1 IGF1R MB MDM2 MYCN
8 endocrine/exocrine gland MP:0005379 10.16 ALK CDK4 FOXO1 IGF1R MDM2 PAX3
9 muscle MP:0005369 10.15 CDK4 DES FOXO1 IGF1R MB MDM2
10 craniofacial MP:0005382 10.14 CDK4 ENO2 FOXO1 IGF1R MDM2 MYCN
11 integument MP:0010771 10.11 ALK CDK4 FOXO1 IGF1R MDM2 MYOG
12 liver/biliary system MP:0005370 10.03 CDK4 FOXO1 IGF1R MDM2 MYCN PAX3
13 neoplasm MP:0002006 10.02 ALK CDK4 FOXO1 IGF1R MDM2 MYOD1
14 no phenotypic analysis MP:0003012 9.91 FOXO1 MDM2 MYCN MYOD1 MYOG PAX3
15 normal MP:0002873 9.9 CDK4 DIABLO FOXO1 MDM2 MYCN MYOD1
16 respiratory system MP:0005388 9.7 ALK ENO2 IGF1R MB MYCN MYOD1
17 skeleton MP:0005390 9.32 ALK CDK4 FOXO1 IGF1R MDM2 MYCN

Drugs & Therapeutics for Rhabdomyosarcoma 2

Drugs for Rhabdomyosarcoma 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1730)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
2
Enoxaparin Approved Phase 4 9005-49-6 772
3
Dalteparin Approved Phase 4 9005-49-6
4
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
5
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
6
Insulin glulisine Approved Phase 4 207748-29-6
7
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
8
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
9
Probucol Approved, Investigational Phase 4 23288-49-5 4912
10
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
11
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
12
Rimonabant Approved, Investigational Phase 4 168273-06-1, 158681-13-1 104850
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
15
Nadolol Approved Phase 4 42200-33-9 39147
16
Lacidipine Approved, Investigational Phase 4 103890-78-4
17 Tangerine Approved Phase 4
18
Captopril Approved Phase 4 62571-86-2 44093
19
Ticlopidine Approved Phase 4 55142-85-3 5472
20
Nitrendipine Approved, Investigational Phase 4 39562-70-4 4507
21
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
22
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
23
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
24
Cetirizine Approved Phase 4 83881-51-0 2678
25
Azelastine Approved Phase 4 58581-89-8 2267
26
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
27
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
28
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
29
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
30
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
31
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
32
Lopinavir Approved Phase 4 192725-17-0 92727
33
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
34
Insulin lispro Approved Phase 4 133107-64-9
35
Fenofibrate Approved Phase 4 49562-28-9 3339
36
Licorice Approved Phase 4
37
Atorvastatin Approved Phase 4 134523-00-5 60823
38
Ezetimibe Approved Phase 4 163222-33-1 150311
39
Fosamprenavir Approved Phase 4 226700-79-4 131536
40
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
41
Misoprostol Approved Phase 4 59122-46-2 5282381
42
Ribavirin Approved Phase 4 36791-04-5 37542
43
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
44
Lumefantrine Approved Phase 4 82186-77-4 6437380
45
Artemether Approved Phase 4 71963-77-4 119380 68911
46
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
47
Simvastatin Approved Phase 4 79902-63-9 54454
48
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
49
Levodopa Approved Phase 4 59-92-7 6047
50
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
2 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
3 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
4 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
5 The Safety、Efficacy and Pharmacokinetics of Dexmedetomidine Administered Through Different Routes in Pediatric Unknown status NCT03337581 Phase 4 Dexmedetomidine
6 Assessment of Implantation Potential of Embryos Cultured by Time-lapse Technology (Embryoscope) Before Transfer in In-vitro Fertilization (IVF) / Intracytoplasmic Sperm Injection (ICSI) Cycles: A Randomized Control Study. Unknown status NCT01760278 Phase 4 recombinant Follicle Stimulating Hormone (rFSH)
7 Botulinum Toxin A for the Treatment of Chronic Lumbar Back Pain: A Prospective Randomized Double-blind Placebo-controlled Crossover Study Unknown status NCT00404417 Phase 4 Botulinum Toxin A / Placebo;Botulinum Toxin A / Botulinum Toxin A;Placebo / Botulinum Toxin A;Placebo / Placebo
8 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
9 Randomized Controlled Trial to Compare the Immunogenicity of Intramuscular Versus Intradermal Trivalent Inactivated Split Virion Influenza Vaccine in HIV-infected Men Who Have Sex With Men in Bangkok, Thailand Unknown status NCT01538940 Phase 4
10 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
11 Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring Unknown status NCT00841308 Phase 4
12 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
13 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
14 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
15 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
16 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
17 Contrast The Role of Microfibrillar Collagen Hemostat Flour(Avitene) And OK-432 (Sapylin)in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4 Avitene;Sapylin
18 Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
19 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
20 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
21 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
22 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
23 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
24 Prospective, Randomized Clinical Trial Comparing Pain Sensation, Seroma Formation and Quality od Life Following BCT With SLND in Breast Cancer Patients Operated With Classic Versus High-frequency Electrocoagulation. Unknown status NCT01216254 Phase 4
25 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
26 The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment Unknown status NCT03130634 Phase 4 Silymarin
27 Role Of Saccharomyces Boulardii In Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
28 Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury Unknown status NCT02530359 Phase 4 Pirfenidone extended release;Placebo equivalent
29 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
30 Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Unknown status NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
31 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
32 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
33 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
34 Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes. Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
35 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
36 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
37 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4 Maraviroc
38 Luteal Phase Support With Progesterone vs Estrogen and Progesterone on Pregnancy Rates in Ovarian Stimulation and Intrauterine Insemination Cycles: a Prospective Randomized Study Unknown status NCT01237535 Phase 4 Luteal support with progesterone only;Luteal support with estrogen + progesterone
39 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
40 Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Unknown status NCT03244241 Phase 4 Insulin Degludec 100 UNT/ML [Tresiba]
41 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
42 Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy Unknown status NCT02317770 Phase 4 Lidocaine Spray;Nebulized Lidocaine
43 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE) Unknown status NCT02361489 Phase 4
44 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
45 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
46 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
47 A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers. Unknown status NCT01734109 Phase 4
48 Analgesic Efficacy of Oral Dexketoprofen Trometamol/Tramadol Hydrochloride Versus Tramadol Hydrochloride/Paracetamol: a Randomised, Double-blind, Placebo and Active-controlled, Parallel Group Study in Moderate to Severe Acute Pain After Removal of Impacted Lower Third Molar (Dexketoprofen Analgesic eVolution wIth tramaDol- DAVID Study) Unknown status NCT02777970 Phase 4 Tramadol Hydrochloride/Dexketoprofen Trometamol;Tramadol Hydrochloride/Paracetamol;Placebo
49 A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP) Unknown status NCT02708446 Phase 4 Mifepristone;Buccal misoprostol;Sublingual misoprostol
50 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg

Search NIH Clinical Center for Rhabdomyosarcoma 2

Cochrane evidence based reviews: rhabdomyosarcoma, alveolar

Genetic Tests for Rhabdomyosarcoma 2

Genetic tests related to Rhabdomyosarcoma 2:

# Genetic test Affiliating Genes
1 Alveolar Rhabdomyosarcoma 29 FOXO1 PAX3 PAX7

Anatomical Context for Rhabdomyosarcoma 2

MalaCards organs/tissues related to Rhabdomyosarcoma 2:

40
Breast, Lung, Prostate, Testes, Bone, Brain, Heart

Publications for Rhabdomyosarcoma 2

Articles related to Rhabdomyosarcoma 2:

(show top 50) (show all 1023)
# Title Authors PMID Year
1
Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. 54 61 56
8643596 1996
2
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. 54 61 56
8275086 1993
3
Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. 54 61 56
8098985 1993
4
Clinical utility gene card for: Alveolar rhabdomyosarcoma. 61 6
21829230 2012
5
Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? 61 56
11556833 2001
6
Localization of the t(2;13) breakpoint of alveolar rhabdomyosarcoma on a physical map of chromosome 2. 61 56
1505949 1992
7
Chromosomal sublocalization of the 2;13 translocation breakpoint in alveolar rhabdomyosarcoma. 61 56
1382566 1992
8
Localization of the rhabdomyosarcoma t(2;13) breakpoint on a physical map of chromosome 13. 61 56
1783402 1991
9
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. 56
12368906 2002
10
Chromosomal analysis of sixteen human rhabdomyosarcomas. 56
3338090 1988
11
Translocation 2;8 in a congenital rhabdomyosarcoma. 56
3342389 1988
12
A specific chromosomal abnormality in rhabdomyosarcoma. 56
3691179 1987
13
The utility of FOXO1 fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded specimens in the diagnosis of alveolar rhabdomyosarcoma. 54 61
19704258 2009
14
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. 54 61
19707204 2009
15
Structural basis for DNA recognition by the human PAX3 homeodomain. 54 61
19199574 2009
16
Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. 54 61
18386058 2008
17
Adult cutaneous alveolar rhabdomyosarcoma on the face diagnosed by the expression of PAX3-FKHR gene fusion transcripts. 54 61
18705836 2008
18
Rhabdomyosarcoma an ubiquitous pediatric tumour. 54 61
18727437 2008
19
Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. 54 61
18414034 2008
20
[Diagnosis of micrometastases of alveolar rhabdomyosarcoma]. 54 61
18540440 2008
21
Comparison of the proximal promoter regions of the PAX3 and PAX7 genes. 54 61
17954266 2007
22
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. 54 61
16140913 2005
23
Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. 54 61
15313887 2004
24
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. 54 61
15184910 2004
25
The MYCN oncoprotein as a drug development target. 54 61
12880971 2003
26
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. 54 61
11863357 2002
27
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. 54 61
11735247 2001
28
Regulating the neoplastic phenotype using engineered transcriptional repressors. 54 61
11164187 2001
29
Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma. 54 61
10700864 2000
30
A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma. 54 61
10616906 1999
31
PAX3 gene structure, alternative splicing and evolution. 54 61
10521655 1999
32
PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. 54 61
10439042 1999
33
The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. 54 61
9858583 1999
34
Expression of WT1 in pediatric small cell tumors: report of two cases with a possible mesothelial origin. 54 61
9841704 1999
35
Normal and rearranged PAX3 expression in human rhabdomyosarcoma. 54 61
9546061 1998
36
Chromosomal translocations involving paired box transcription factors in human cancer. 54 61
9570138 1997
37
The genomic organization and the full coding region of the human PAX7 gene. 54 61
9339373 1997
38
Translin recognition site sequences flank chromosome translocation breakpoints in alveolar rhabdomyosarcoma cell lines. 54 61
9294613 1997
39
[Pathologic diagnosis on bone and soft tissue tumors by molecular biological methods]. 54 61
9256013 1997
40
Expression of PAX3 in Ewing's sarcoma family of tumors. 54 61
9169092 1997
41
Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. 54 61
8889501 1996
42
Cytogenetics and tissue culture of small round cell tumors of bone and soft tissue. 54 61
8875708 1996
43
Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. 54 61
9052994 1996
44
MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). 54 61
8751388 1996
45
Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. 54 61
8634710 1995
46
The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator. 54 61
7630639 1995
47
Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. 54 61
7624119 1995
48
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. 54 61
8083365 1994
49
Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. 54 61
8221646 1993
50
Orbital rhabdomyosarcoma. Immunohistochemical studies of seven cases. 54 61
2119961 1990

Variations for Rhabdomyosarcoma 2

ClinVar genetic disease variations for Rhabdomyosarcoma 2:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PAX7 NM_001135254.2(PAX7):c.220C>T (p.Arg74Ter)SNV Likely pathogenic 689508 1:18960931-18960931 1:18634437-18634437
2 APC NM_000038.6(APC):c.449A>G (p.Lys150Arg)SNV Uncertain significance 141928 rs371085910 5:112111352-112111352 5:112775655-112775655
3 PAX3 NM_181458.4(PAX3):c.540C>G (p.Ser180Arg)SNV Uncertain significance 504788 rs200679164 2:223158932-223158932 2:222294213-222294213
4 PAX3 NM_181458.4(PAX3):c.580G>A (p.Glu194Lys)SNV Uncertain significance 504786 rs148454691 2:223158892-223158892 2:222294173-222294173

Cosmic variations for Rhabdomyosarcoma 2:

9 (show top 50) (show all 679)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87906219 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.728T>C p.M243T 17:7674235-7674235 8
2 COSM88149182 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.668C>G p.P223R 17:7674863-7674863 8
3 COSM87949760 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.871A>C p.K291Q 17:7673749-7673749 8
4 COSM88120884 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.739A>G p.N247D 17:7674224-7674224 8
5 COSM87911460 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.961A>T p.K321* 17:7673567-7673567 8
6 COSM87900604 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.637C>T p.R213* 17:7674894-7674894 8
7 COSM87898463 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.733G>T p.G245C 17:7674230-7674230 8
8 COSM88205650 TP53 soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.611A>G p.E204G 17:7674920-7674920 8
9 COSM87898578 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.733G>A p.G245S 17:7674230-7674230 8
10 COSM87897745 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 8
11 COSM87897839 TP53 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 8
12 COSM87898351 TP53 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.743G>A p.R248Q 17:7674220-7674220 8
13 COSM88094731 SOX9 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.76A>G p.M26V 17:72121467-72121467 8
14 COSM84133785 RICTOR soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 8
15 COSM97041246 PTPRT soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2277G>T p.Q759H 20:42248779-42248779 8
16 COSM146438832 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.214G>A p.A72T 12:112450394-112450394 8
17 COSM146438781 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.226G>C p.E76Q 12:112450406-112450406 8
18 COSM146439443 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1520G>T p.G507V 12:112489084-112489084 8
19 COSM146438825 PTPN11 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.205G>A p.E69K 12:112450385-112450385 8
20 COSM90839845 PTCH1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.208G>A p.A70T 9:95506593-95506593 8
21 COSM90587293 POLE soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.5975G>C p.C1992S 12:132634215-132634215 8
22 COSM96437477 PIK3CG soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.2638G>A p.E880K 7:106883041-106883041 8
23 COSM87132301 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.1624G>A p.E542K 3:179218294-179218294 8
24 COSM87132544 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,alveolar c.1636C>A p.Q546K 3:179218306-179218306 8
25 COSM87132245 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3140A>G p.H1047R 3:179234297-179234297 8
26 COSM87132308 PIK3CA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1633G>A p.E545K 3:179218303-179218303 8
27 COSM88818803 PDGFRA soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3195G>C p.E1065D 4:54295197-54295197 8
28 COSM97687376 NTRK3 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.492C>A p.C164* 15:88137534-88137534 8
29 COSM97107326 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.181C>A p.Q61K 1:114713909-114713909 8
30 COSM97107379 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>A p.G12D 1:114716126-114716126 8
31 COSM97107772 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 1:114716124-114716124 8
32 COSM97107813 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 1:114716127-114716127 8
33 COSM97107359 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>G p.Q61R 1:114713908-114713908 8
34 COSM97107717 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.38G>T p.G13V 1:114716123-114716123 8
35 COSM97107724 NRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 1:114716127-114716127 8
36 COSM87643288 NOTCH1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.3277T>C p.Y1093H 9:136508280-136508280 8
37 COSM93680412 NF1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.7870G>C p.A2624P 17:31357269-31357269 8
38 COSM84820183 MYOD1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.365T>G p.L122R 11:17720147-17720147 8
39 COSM101727756 MAP3K1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1337G>A p.C446Y 5:56871945-56871945 8
40 COSM87804028 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.38G>A p.G13D 12:25245347-25245347 8
41 COSM87804083 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>C p.G12A 12:25245350-25245350 8
42 COSM87808527 KRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.182A>T p.Q61L 12:25227342-25227342 8
43 COSM87690443 KMT2D soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1291G>T p.E431* 12:49052392-49052392 8
44 COSM102156541 KDM6A soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.493C>T p.R165* 23:45020659-45020659 8
45 COSM112988832 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.37G>C p.G13R 11:534286-534286 8
46 COSM112988997 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>T p.G12C 11:534289-534289 8
47 COSM112989371 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.34G>A p.G12S 11:534289-534289 8
48 COSM112988917 HRAS soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.35G>T p.G12V 11:534288-534288 8
49 COSM98439571 GATA1 soft tissue,striated muscle,rhabdomyosarcoma,pleomorphic c.1099C>A p.L367M 23:48794021-48794021 8
50 COSM107501436 FGFR1 soft tissue,striated muscle,rhabdomyosarcoma,embryonal c.1704G>T p.M568I 8:38417358-38417358 8

Copy number variations for Rhabdomyosarcoma 2 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 25460 1 18957499 19075360 Amplification PAX7 Alveolar rhabdomyosarcoma
2 76221 13 28900000 50900000 Amplification FOXO1A Alveolar rhabdomyosarcoma
3 141698 2 215300000 221500000 Amplification PAX3 Alveolar rhabdomyosarcoma

Expression for Rhabdomyosarcoma 2

Search GEO for disease gene expression data for Rhabdomyosarcoma 2.

Pathways for Rhabdomyosarcoma 2

GO Terms for Rhabdomyosarcoma 2

Cellular components related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.1 PAX7 PAX3 MYOG MYOD1 MYCN FOXO1

Biological processes related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.97 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.95 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
3 negative regulation of apoptotic process GO:0043066 9.93 WT1 PAX7 MDM2 IGF1R FOXO1
4 heart development GO:0007507 9.81 WT1 TH MDM2 MB
5 regulation of gene expression GO:0010468 9.8 PAX7 MYOD1 MDM2 CDK4
6 cellular response to growth factor stimulus GO:0071363 9.63 TH MYOG MDM2
7 positive regulation of transcription, DNA-templated GO:0045893 9.63 WT1 PAX3 MYOG MYOD1 MYCN FOXO1
8 myotube differentiation GO:0014902 9.52 MYOG MYOD1
9 positive regulation of skeletal muscle fiber development GO:0048743 9.48 MYOG MYOD1
10 cellular response to alkaloid GO:0071312 9.43 TH MDM2
11 skeletal muscle tissue development GO:0007519 9.43 PAX7 MYOG MYOD1
12 muscle cell fate commitment GO:0042693 9.32 MYOG MYOD1
13 response to ether GO:0045472 8.96 TH MDM2
14 muscle organ development GO:0007517 8.92 PAX7 PAX3 MYOG MYOD1

Molecular functions related to Rhabdomyosarcoma 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.63 WT1 PAX7 PAX3 MYOG MYOD1 FOXO1
2 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.5 WT1 PAX7 PAX3 MYOG MYOD1 MYCN
3 DNA-binding transcription factor activity GO:0003700 9.17 WT1 PAX7 PAX3 MYOG MYOD1 MYCN

Sources for Rhabdomyosarcoma 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....